PCDHB19P: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: PCDHB19P

NCBI ID: G84054

Other Name(s): PCDH-PSI5 | PCDHB19 | protocadherin beta 19 pseudogene | Protocadherin beta 19 pseudogene

PCDHB19P: A Potential Drug Target and Biomarker for Neurological Disorders

PCDHB19P (PCDH-PSI5) is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. It is a member of the PCDH gene family, which is known for its role in the development of neural crest cells, which are a type of cell that gives rise to a variety of tissues in the body, including brain and heart.

PCDHB19P is a transmembrane protein that is expressed in the brain and is involved in the development and progression of various neurological disorders, including Alzheimer's disease. It is a member of the PCDH gene family, which is known for its role in the development of neural crest cells, which are a type of cell that gives rise to a variety of tissues in the body, including brain and heart.

One of the most promising aspects of PCDHB19P is its potential as a drug target. By targeting this protein, researchers may be able to develop new treatments for a variety of neurological disorders. Additionally, PCDHB19P may also be a useful biomarker for tracking the progression of these disorders.

In addition to its potential as a drug target, PCDHB19P is also a promising biomarker for the diagnosis and treatment of neurological disorders. By studying the levels of this protein in the brain, researchers may be able to develop new diagnostic tests for a variety of disorders, as well as new treatments.

Overall, PCDHB19P is a protein that is worth further research as a potential drug target and biomarker for the diagnosis and treatment of neurological disorders.

Protein Name: Protocadherin Beta 19 Pseudogene

More Common Targets

AREAS

Q&A

STOCKS

TARGETS

CONTACT

BD@bio.cacnex.com